Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1 1

Status

Recruiting 12Completed 11Unknown 8Active not recruiting 5Withdrawn 3Terminated 3Not yet recruiting 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Genitourinary 1

Conditions

Neoplasms 1Lung Neoplasms 1Infiltrating Bladder Urothelial Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Radiation Dose Hypofractionation × Clear all
NCT05161533 2023-10-18

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

University of Washington

Phase 2 Withdrawn
Thoracic

Lung Neoplasms

NCT03419130 2018-12-07

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

University of California, San Francisco

Phase 2 Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

NCT02947113 2017-11-30

HYPOLAN

The Netherlands Cancer Institute

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡